Eric Burks, MD

Eric Burks, MD, studies screening-detected non-small cell lung cancer. Dr. Burks’ studies established the diagnostic criteria for an entity now known as pulmonary adenocarcinoma of low malignant potential (LMP) which has been internationally validated and shown to account for overdiagnosis in the National Lung Screening Trial (NLST). His work has further established angioinvasive lung adenocarcinoma as the most aggressive form of early-stage NSCLC. Patients with small (<2 cm) angioinvasive tumors benefit from surgical resection of the entire involved lung lobe whereas the remaining patients are adequately treated with parenchymal sparing approaches such as wedge resection. Dr. Burks is a provisional patent holder (BU-2023-026) for biomarkers associated with angioinvasive lung adenocarcinoma, a co-investigator on a U01, The Lung Pre-Cancer Atlas project, a site PI on two R01s and a co-PI on an American Society of Hematology grant. In addition, he directs hematopathology, the hematology laboratory, the immunohistochemistry and special procedures laboratory, including amyloid pathology, and the hemoglobin diagnostic reference laboratory at Boston Medical Center.

Website

Google Scholar